You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
What if HIV were unable to develop resistance against a new therapeutic agent?
|
|---|---|
| Published in |
BMC Medicine, November 2013
|
| DOI | 10.1186/1741-7015-11-249 |
| Pubmed ID | |
| Authors |
Mark A Wainberg, Thibault Mesplède, Francois Raffi |
| Abstract |
The HIV integrase inhibitor, Dolutegravir (DTG), was recently approved by the Food and Drug Administration in the United States and is the only HIV drug that has not selected for resistance mutations in the clinic when used as part of first-line therapy. This has led to speculation that DTG might have a higher genetic barrier for the development of drug resistance than the other compounds that are used in therapy. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 17% |
| United States | 2 | 17% |
| Netherlands | 1 | 8% |
| Unknown | 7 | 58% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 50% |
| Practitioners (doctors, other healthcare professionals) | 3 | 25% |
| Scientists | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Italy | 1 | 2% |
| Unknown | 42 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 23% |
| Student > Ph. D. Student | 7 | 16% |
| Other | 6 | 14% |
| Student > Master | 6 | 14% |
| Student > Bachelor | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 6 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 30% |
| Agricultural and Biological Sciences | 8 | 18% |
| Biochemistry, Genetics and Molecular Biology | 6 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Immunology and Microbiology | 2 | 5% |
| Other | 5 | 11% |
| Unknown | 7 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#2,470,902
of 24,938,276 outputs
Outputs from BMC Medicine
#1,623
of 3,890 outputs
Outputs of similar age
#27,486
of 314,983 outputs
Outputs of similar age from BMC Medicine
#35
of 57 outputs
Altmetric has tracked 24,938,276 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,890 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.3. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,983 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.